Okada K, Ichii S, Hatada T, Ishii H, Utsunomiya J
Second Department of Surgery, Hyogo College of Medicine, 1-1 Mukogawa-cho, Nishinomiya, Hyogo 663-8501, Japan.
Int J Oncol. 1998 May;12(5):1025-8. doi: 10.3892/ijo.12.5.1025.
To investigate whether estrogen receptor abnormalities are associated with resistance of breast cancer to endocrine therapy, we compared estrogen receptor mRNA between normal breast tissue and carcinoma. Using the RT-PCR, paired cancer and normal breast tissue specimens from 15 patients were analyzed. Exon-deleted variants were found in both tumor and normal tissue, with differences of variant expression between normal and tumor tissue being observed. One patient showed multiple deletions in the hormone-binding domain. Alterations in the amount and/or kind of variant ER expression may be important in determining the response of breast cancer to endocrine therapy.
为了研究雌激素受体异常是否与乳腺癌对内分泌治疗的耐药性相关,我们比较了正常乳腺组织和癌组织中雌激素受体mRNA的情况。使用逆转录聚合酶链反应(RT-PCR),对15例患者的配对癌组织和正常乳腺组织标本进行了分析。在肿瘤组织和正常组织中均发现了外显子缺失变体,且观察到正常组织和肿瘤组织之间变体表达存在差异。1例患者在激素结合域出现多处缺失。雌激素受体(ER)变体表达量和/或种类的改变可能在决定乳腺癌对内分泌治疗的反应中起重要作用。